QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer

计划入组 25 人 · 首次发布于 2025 年 9 月 22 日

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

计划入组 31 人 · 首次发布于 2026 年 3 月 16 日

Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma

计划入组 6 人 · 首次发布于 2017 年 9 月 19 日

ARAC-02

Boltbody ISAC PD-L1(Bolt Bio)

PD-RX Pharmaceuticals, Inc.

United States

NHI-1

United States

CLEVELAND CLINIC ABUDHABI L L C

United Arab Emirates

Combination Immunotherapies Show Promise in Pancreatic Cancer Treatment

BeyondSpring's Plinabulin Shows Consistent Survival Benefit in EGFR Wild-Type NSCLC After Anti-PD-(L)1 Failure

BMS-986253 Fails to Improve Outcomes in Advanced Melanoma Post-PD-1/L1 Therapy